<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Guanfacine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Guanfacine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Guanfacine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8510" href="/d/html/8510.html" rel="external">see "Guanfacine: Drug information"</a> and <a class="drug drug_patient" data-topicid="11750" href="/d/html/11750.html" rel="external">see "Guanfacine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F178166"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Intuniv</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867090"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Guanfacine XR;</li>
<li>Intuniv XR;</li>
<li>JAMP-Guanfacine XR</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1017394"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Alpha<sub>2</sub>-Adrenergic Agonist</span></li></ul></div>
<div class="block dop drugH1Div" id="F9612512"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Manufacturer labeling states immediate-release and extended-release products are not interchangeable on a mg-per-mg basis due to differences in pharmacokinetic profiles.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fc8a7e32-2b4e-402d-ae6a-0c132cdad29a">Attention-deficit/hyperactivity disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Attention-deficit/hyperactivity disorder (ADHD):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Use is suggested in patients who are intolerant of or lacked a response to stimulants; an adequate stimulant trial of at least 6 weeks suggested prior to initiating guanfacine; not typically used first-line (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31570648','lexi-content-ref-NICE.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31570648','lexi-content-ref-NICE.1'])">Ref</a></span>). Guanfacine may be an optimal selection for patients with tics or Tourette syndrome comorbidity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31061208','lexi-content-ref-NICE.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31061208','lexi-content-ref-NICE.1'])">Ref</a></span>) or if stimulant diversion or misuse is a concern. May be used as monotherapy or as adjunctive with ongoing stimulant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31570648','lexi-content-ref-NICE.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31570648','lexi-content-ref-NICE.1'])">Ref</a></span>). Dosing is different for patients with autism spectrum disorder and ADHD comorbidity; see "Autism spectrum disorder (ASD) and ADHD (comorbidity)."</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate-release product: Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19476419','lexi-content-ref-17581453']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19476419','lexi-content-ref-17581453'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥6 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">≤45 kg: Oral: Initial: 0.5 mg once daily at bedtime; may titrate every 3 to 4 days in 0.5 mg/day increments to 0.5 mg twice daily, then 0.5 mg three times daily, then 0.5 mg four times daily; maximum daily dose: Patient weight 27 to 40.5 kg: 2 mg/<b>day</b>; 40.5 to 45 kg: 3 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;45 kg: Oral: Initial: 1 mg once daily at bedtime; may titrate every 3 to 4 days in 1 mg/day increments to 1 mg twice daily, then 1 mg three times daily, then 1 mg four times daily; maximum daily dose: 4 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Extended-release product (eg, Intuniv):</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents 6 to 17 years: Oral: Initial: 1 mg once daily administered at the same time of day (in the morning or evening); may titrate dose by no more than 1 mg/week increments based upon response and as tolerated to the recommended target dose range: 0.05 to 0.12 mg/kg/day or 1 to 7 mg/day. Target range based on data from monotherapy trials to balance the exposure (dose)-related potential benefits and risks (hypotension, bradycardia, and sedative effects). In clinical monotherapy trials, initial clinical response was associated with doses of 0.05 to 0.08 mg/kg once daily; increased efficacy was seen with increasing mg/kg doses; doses up to 0.12 mg/kg once daily have shown benefit when tolerated. In adjunctive therapy trials with stimulant medication, doses of 0.05 to 0.12 mg/kg/day produced optimal clinical response in the majority of patients.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Suggested fixed target dose range for patients weighing ≥25 kg:</i> All doses administered once daily at the same time (either in the morning or evening) not to exceed age-based maximum daily doses:</p>
<p style="text-indent:-2em;margin-left:10em;">25 to 33.9 kg: 2 to 3 mg/day.</p>
<p style="text-indent:-2em;margin-left:10em;">34 to 41.4 kg: 2 to 4 mg/day.</p>
<p style="text-indent:-2em;margin-left:10em;">41.5 to 49.4 kg: 3 to 5 mg/day.</p>
<p style="text-indent:-2em;margin-left:10em;">49.5 to 58.4 kg: 3 to 6 mg/day.</p>
<p style="text-indent:-2em;margin-left:10em;">58.5 to 91 kg: 4 to 7 mg/day.</p>
<p style="text-indent:-2em;margin-left:10em;">&gt;91 kg: 5 to 7 mg/day.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Maximum daily doses:</i> Doses above the following have not been evaluated:</p>
<p style="text-indent:-2em;margin-left:10em;">Monotherapy: Children 6 to 12 years: 4 mg/<b>day</b>; Adolescents: 13 to 17 years: 7 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:10em;">Adjunct therapy (with psychostimulants): 4 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Conversion from immediate-release guanfacine to the extended-release product:</i> Discontinue the immediate-release product; initiate the extended-release product at the doses recommended above.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Missed doses of extended release:</i> If patient misses ≥2 consecutive doses, repeat titration of dose should be considered.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Discontinuation of extended release:</i> Taper dose by no more than 1 mg every 3 to 7 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e48b3c83-a680-47a7-aa44-346478611a4a">Autism spectrum disorder and ADHD</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Autism spectrum disorder (ASD) and ADHD (comorbidity):</b> Limited data available; efficacy results variable:</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents 5 to 14 years: Immediate-release product:</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;25 kg: Oral: Initial: 0.25 mg once daily, increase dose as tolerated every 4 days in 0.25 mg/day increments in 2 to 3 divided doses; maximum daily dose: 3 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17069547']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17069547'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">≥25 kg: Oral: Initial: 0.5 mg once daily, increase dose as tolerated every 4 days in 0.5 mg/day increments in 2 to 3 divided doses; maximum daily dose: 3 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18552703','lexi-content-ref-17069547']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18552703','lexi-content-ref-17069547'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Dosing based on a double-blind, placebo-controlled, 6-week crossover trial conducted in children with ADHD and autism or intellectual disabilities (n=11; age: 5 to 9 years); five of 11 patients showed improvement in hyperactivity scores; other patient assessment parameters did not show improvements (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18552703']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18552703'])">Ref</a></span>). In an open-label, 8-week pilot study in children with ADHD and ASD (n=25; mean age: 9 years; range: 5 to 14 years), patients showed improvement in parent- and teacher-rated hyperactivity subscale scores; increased irritability occurred in 7 patients; the authors note that patients with ASD may be more sensitive to irritability-type adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17069547']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17069547'])">Ref</a></span>). A retrospective chart review of pediatric ASD (n=80; age: 3 to 18 years) reported ~24% of patients responded to mean dose of 2.6 mg/day; the authors noted using <i>Diagnostic and Statistical Manual of Mental Disorders</i> criteria at the time of the trial, patients with Asperger syndrome or Pervasive Developmental Disorder not otherwise specified (PDD-NOS) responded more frequently than those with autistic disorder or comorbidity of intellectual disability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15319020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15319020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc4b3de7-1b7f-4f34-9c5e-fb2c0aab85f9">Hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension:</b>
<b>Note:</b> Although FDA approved for hypertension, pediatric consensus guidelines do not include guanfacine as a therapeutic option; use has been replaced by other agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28827377']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28827377'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Immediate-release product: Oral: 1 mg usually at bedtime; may increase, if needed, at 3- to 4-week intervals; usual range: 0.5 to 2 mg/day; maximum daily dose: 2 mg/<b>day</b>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="308cbb9f-ebfb-4bbc-90ee-cd1c4f6c900c">Tourette syndrome, tic disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tourette syndrome, Tic disorder:</b> Limited data available; efficacy results variable: Compared to placebo, guanfacine is possibly more likely to reduce tic severity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31061208']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31061208'])">Ref</a></span>); however, other trials have not conferred similar results using extended-release guanfacine for chronic tic disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28723227']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28723227'])">Ref</a></span>); in patients with ADHD as a comorbidity, greater efficacy has been shown (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24290467','lexi-content-ref-31061208']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24290467','lexi-content-ref-31061208'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents 6 to 16 years: Immediate-release product: Oral: Initial: 0.5 mg once daily at bedtime for 3 days, then 0.5 mg twice daily for 4 days, then 0.5 mg 3 times daily for 7 days; further upward titration based on clinical response to maximum daily dose: 4 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11431228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11431228'])">Ref</a></span>); twice-daily dosing may be effective for some patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7559307','lexi-content-ref-12469007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7559307','lexi-content-ref-12469007'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Dosing based on a double-blind, placebo-controlled study in patients with ADHD and mild to moderate tics (n=34; mean age: 10.4 years; range: 7 to 14 years); reported final dose range: 1.5 to 3 mg/day in 3 divided doses with the most common dose reported was 2.5 mg/day (ie, 1 mg in morning, 0.5 mg at 3 pm, and 1 mg at bedtime); a statistically significant decrease (31%) in tic scores and improvement in teacher-rated ADHD scores was reported after 8 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11431228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11431228'])">Ref</a></span>). A small open-label trial of patients with Tourette syndrome and ADHD (n=10; age range: 8 to 16 years) used similar initial doses and dose titration (0.5 mg increments every 3 to 4 days); final reported dose range: 0.75 to 3 mg/day in divided doses (2 to 3 times daily); seven of 10 patients required a final dose of 1.5 mg/day in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7559307']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7559307'])">Ref</a></span>). A short 4-week trial evaluating 24 patients (age range: 6 to 16 years) with mild chronic tic disorder showed only slight improvement in tic scores after titration (over approximately 3 weeks) to a final dose of 2 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12469007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12469007'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51112865"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Immediate release: Children ≥12 years and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; however, the lower end of the dosing range is recommended in patients with renal impairment; use with caution, as ~50% of the dose (40% to 75% of dose) is excreted as unchanged drug in urine.</p>
<p style="text-indent:-2em;margin-left:2em;">Extended release (Intuniv): Children ≥6 years and Adolescents: There are no dosage adjustments provided in manufacturer's labeling (has not been studied); however, dosage adjustments may be necessary in patients with significant renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Immediate release or extended release: Dialysis clearance is low (~15% of total clearance).</p></div>
<div class="block dohp drugH1Div" id="F51112866"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Immediate release: Children ≥12 years and Adolescents: There are no specific dosage adjustments provided in the manufacturer's labeling; however, use with caution in chronic hepatic impairment; consider dosage reduction.</p>
<p style="text-indent:-2em;margin-left:2em;">Extended release (Intuniv): Children ≥6 years and Adolescents: There are no dosage adjustments provided in manufacturer's labeling (has not been studied); however, dosage adjustments may be necessary in patients with significant hepatic impairment.</p></div>
<div class="block doa drugH1Div" id="F178170"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8510" href="/d/html/8510.html" rel="external">see "Guanfacine: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc4b3de7-1b7f-4f34-9c5e-fb2c0aab85f9">Hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension (alternative agent):</b> Immediate release: Oral: Initial: 0.5 to 1 mg once daily at bedtime; may increase as needed after 3 to 4 weeks up to 2 mg once daily at bedtime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356'])">Ref</a></span>). <b>Note:</b> Adverse reactions increase significantly with doses above 3 mg/day.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990954"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Immediate release: There are no specific dosage adjustments provided in the manufacturer’s labeling; however, the lower end of the dosing range is recommended in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Immediate release or extended release: Dialysis clearance is low (~15% of total clearance).</p></div>
<div class="block doha drugH1Div" id="F50988303"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Immediate release: There are no dosage adjustments provided in the manufacturer’s labeling; however, use with caution in chronic hepatic impairment.</p></div>
<div class="block arsc drugH1Div" id="F57147110"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular effects including <b>atrioventricular </b>(AV) <b>block</b>, <b>bradycardia</b>, <b>hypotension</b>, <b>orthostatic hypotension</b>, <b>sinoatrial nodal rhythm disorder</b>, and <b>syncope</b> may occur with guanfacine use in all ages (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32905677','lexi-content-ref-23160939','lexi-content-ref-18427125']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32905677','lexi-content-ref-23160939','lexi-content-ref-18427125'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>
<i>:</i> Dose-related; related to the pharmacologic action (ie, stimulates alpha-2 adrenergic receptors resulting in decreased sympathetic activity leading to decreased heart rate, peripheral resistance, cardiac output, and blood pressure) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Shanahan.1','lexi-content-ref-23757186']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Shanahan.1','lexi-content-ref-23757186'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; occur most often in the first month of therapy and are usually transient. Tolerance to hypotensive effect develops with continued use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23160939']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23160939'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i></p>
<p style="text-indent:-2em;margin-left:6em;">• History of bradycardia, hypotension, or syncope</p>
<p style="text-indent:-2em;margin-left:6em;">• Dehydration</p>
<p style="text-indent:-2em;margin-left:6em;">• Cardiovascular disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23160939']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23160939'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cardiac conduction abnormalities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23160939']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23160939'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of sympatholytic medications (eg, beta blockers, alpha blockers, mixed α,β-blockers)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent antihypertensives</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">CNS effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">CNS effects including <b>drowsiness</b>, <b>insomnia</b>, <b>sedated state</b>, and <b>headache </b>have been reported in adult and pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24472251','lexi-content-ref-32394557','lexi-content-ref-34607580','lexi-content-ref-22176941']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24472251','lexi-content-ref-32394557','lexi-content-ref-34607580','lexi-content-ref-22176941'])">Ref</a></span>). Sedation and drowsiness may impair physical or mental abilities. Although not life-threatening, these effects commonly result in nonadherence and/or discontinuation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24472251']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24472251'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>
<i>: </i>Dose-related; related to the pharmacologic action (ie, activates alpha-2 adrenoreceptors which inhibits the release of norepinephrine [needed for arousal]), CNS effects result when norepinephrine is not present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6994783','lexi-content-ref-19833104','lexi-content-ref-23757186']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6994783','lexi-content-ref-19833104','lexi-content-ref-23757186'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Intermediate; occurs early in treatment (ie, first few weeks after initiation) and with dose increases; transient and usually resolve with continued use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30064718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30064718'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant treatment with medications with sedative effects (eg, antihistamines, centrally active depressants such phenothiazines, barbiturates, benzodiazepines)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant alcohol use</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Withdrawal syndrome/rebound Hypertension</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Withdrawal syndrome including symptoms resembling nervousness and <b>anxiety </b>(eg, increased heart rate), and <b>rebound hypertension</b> may occur with abrupt discontinuation of guanfacine in all ages (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23160939']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23160939'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>
<i>:</i> Withdrawal; result of excessive plasma catecholamine levels, “catecholamine surge”.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; Gradual increase back to baseline pretreatment blood pressures after drug discontinuation; blood pressure readings significantly above pretreatment readings have also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6150002']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6150002'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6150002']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6150002'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6150002']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6150002'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Abrupt discontinuation of guanfacine (eg, medication nonadherence, vomiting [abrupt inability to absorb oral dosage forms]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23160939']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23160939'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F178146"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Immediate release:</b></p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Constipation (2% to 15%), xerostomia (10% to 54%)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Dizziness (12% to 15%), drowsiness (5% to 39%)<span class="lexi-table-link-container"> (<a aria-label="Drowsiness (Immediate Release) table link" class="lexi-table-link" data-table-id="lexi-content-drowsiness-immediate-release" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-drowsiness-immediate-release')">table 1</a>)</span><span class="table-link" style="display:none;">Drowsiness (Immediate Release)</span>, headache (3% to 13%)<span class="lexi-table-link-container"> (<a aria-label="Headache (Immediate Release) table link" class="lexi-table-link" data-table-id="lexi-content-headache-immediate-release" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-headache-immediate-release')">table 2</a>)</span><span class="table-link" style="display:none;">Headache (Immediate Release)</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Drowsiness (Immediate Release)" frame="border" id="lexi-content-drowsiness-immediate-release" rules="all">
<caption style="text-align:center;">
<b>Guanfacine: Adverse Reaction: Drowsiness (Immediate Release)</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Guanfacine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Guanfacine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">39%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild to moderate hypertension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">59</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">59</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 mg daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild to moderate hypertension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">60</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">59</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 mg daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild to moderate hypertension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">61</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">59</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.5 mg daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild to moderate hypertension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">60</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">59</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Headache (Immediate Release)" frame="border" id="lexi-content-headache-immediate-release" rules="all">
<caption style="text-align:center;">
<b>Guanfacine: Adverse Reaction: Headache (Immediate Release)</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Guanfacine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Guanfacine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild to moderate hypertension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">61</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">59</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.5 mg daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild to moderate hypertension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">60</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">59</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 mg</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild to moderate hypertension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">60</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">59</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Immediate-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mild to moderate hypertension</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">59</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">59</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Genitourinary: Impotence (3% to 7%)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Asthenia (2% to 7%), fatigue (5% to 10%)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Extended release</b> (adverse events occurred with children and adolescents 6 to 17 years of age unless otherwise specified):</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Abdominal pain (8% to 19%), decreased appetite (5% to 15%) (van Stralen 2021)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Dizziness (4% to 16%), drowsiness (28% to 57%; including sedated state)<span class="lexi-table-link-container"> (<a aria-label="Drowsiness (Extended Release) table link" class="lexi-table-link" data-table-id="lexi-content-drowsiness-extended-release" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-drowsiness-extended-release')">table 3</a>)</span><span class="table-link" style="display:none;">Drowsiness (Extended Release)</span>, fatigue (10% to 22%), headache (16% to 28%)<span class="lexi-table-link-container"> (<a aria-label="Headache (Extended Release) table link" class="lexi-table-link" data-table-id="lexi-content-headache-extended-release" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-headache-extended-release')">table 4</a>)</span><span class="table-link" style="display:none;">Headache (Extended Release)</span>, insomnia (6% to 13%)<span class="lexi-table-link-container"> (<a aria-label="Guanfacine: Adverse Reaction: Insomnia (Extended Release) table link" class="lexi-table-link" data-table-id="lexi-content-guanfacine-adverse-reaction-insomnia-extended-release" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-guanfacine-adverse-reaction-insomnia-extended-release')">table 5</a>)</span><span class="table-link" style="display:none;">Guanfacine: Adverse Reaction: Insomnia (Extended Release)</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Drowsiness (Extended Release)" frame="border" id="lexi-content-drowsiness-extended-release" rules="all">
<caption style="text-align:center;">
<b>Guanfacine: Adverse Reaction: Drowsiness (Extended Release)</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Guanfacine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Guanfacine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">57%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Flexible dose</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">107</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">112</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Morning dose</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">54%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">23%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Flexible dose</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">157</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">155</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">54%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Flexible dose</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">114</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">112</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Evening dose</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">51%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4 mg daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">151</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">149</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">38%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">151</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">149</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">30%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 mg daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">150</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">149</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">28%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 mg daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">61</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">149</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Headache (Extended Release)" frame="border" id="lexi-content-headache-extended-release" rules="all">
<caption style="text-align:center;">
<b>Guanfacine: Adverse Reaction: Headache (Extended Release)</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Guanfacine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Guanfacine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">28%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4 mg daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">151</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">149</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">27%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Flexible dose</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">157</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">155</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">26%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 mg daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">61</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">149</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">25%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 mg daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">150</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">149</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Flexible dose</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">107</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">112</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Morning dose</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">19%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">151</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">149</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Flexible dose</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">114</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">112</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Evening dose</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Guanfacine: Adverse Reaction: Insomnia (Extended Release)" frame="border" id="lexi-content-guanfacine-adverse-reaction-insomnia-extended-release" rules="all">
<caption style="text-align:center;">
<b>Guanfacine: Adverse Reaction: Insomnia (Extended Release)</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Guanfacine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Guanfacine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">13%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Flexible dose</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">157</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">155</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Flexible dose</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">107</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">112</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Morning dose</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Flexible dose</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">114</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">112</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Evening dose</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Bradycardia (5%)<span class="lexi-table-link-container"> (<a aria-label="Bradycardia (Extended Release) table link" class="lexi-table-link" data-table-id="lexi-content-bradycardia-extended-release" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-bradycardia-extended-release')">table 6</a>)</span><span class="table-link" style="display:none;">Bradycardia (Extended Release)</span>, first-degree atrioventricular block (≥2%), hypotension (4% to 9%)<span class="lexi-table-link-container"> (<a aria-label="Hypotension (Extended Release) table link" class="lexi-table-link" data-table-id="lexi-content-hypotension-extended-release" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hypotension-extended-release')">table 7</a>)</span><span class="table-link" style="display:none;">Hypotension (Extended Release)</span>, increased blood pressure (≥2%), orthostatic hypotension (1% to 5%)<span class="lexi-table-link-container"> (<a aria-label="Orthostatic Hypotension (Extended Release) table link" class="lexi-table-link" data-table-id="lexi-content-orthostatic-hypotension-extended-release" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-orthostatic-hypotension-extended-release')">table 8</a>)</span><span class="table-link" style="display:none;">Orthostatic Hypotension (Extended Release)</span>, sinoatrial nodal rhythm disorder (≥2%), syncope (≥1%), tachycardia (≥2%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Bradycardia (Extended Release)" frame="border" id="lexi-content-bradycardia-extended-release" rules="all">
<caption style="text-align:center;">
<b>Guanfacine: Adverse Reaction: Bradycardia (Extended Release)</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Guanfacine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Guanfacine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Flexible dose</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">157</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">155</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hypotension (Extended Release)" frame="border" id="lexi-content-hypotension-extended-release" rules="all">
<caption style="text-align:center;">
<b>Guanfacine: Adverse Reaction: Hypotension (Extended Release)</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Guanfacine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Guanfacine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Flexible dose</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">157</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">155</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 mg daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">61</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">149</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4 mg daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">151</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">149</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3 mg daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">151</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">149</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Flexible dose</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">107</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">112</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Morning dose</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2 mg daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">150</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">149</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Flexible dose</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">114</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">112</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Evening dose</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Orthostatic Hypotension (Extended Release)" frame="border" id="lexi-content-orthostatic-hypotension-extended-release" rules="all">
<caption style="text-align:center;">
<b>Guanfacine: Adverse Reaction: Orthostatic Hypotension (Extended Release)</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Guanfacine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Guanfacine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Flexible dose</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">157</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">155</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 mg to 4 mg daily</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">513</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">149</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Pruritus (2%), skin rash (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:6em;">Endocrine &amp; metabolic: Weight gain (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:6em;">Gastrointestinal: Abdominal distress (2%), constipation (2% to 4%), diarrhea (2% to 6%), dyspepsia (≥2%), nausea (5% to 7%), stomach discomfort (2%), vomiting (2% to 7%), xerostomia (3% to 8%)</p>
<p style="text-indent:-2em;margin-left:6em;">Genitourinary: Urinary incontinence (2% to 5%)</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Agitation (≥2%), anxiety (5%)<span class="lexi-table-link-container"> (<a aria-label="Anxiety (Extended Release) table link" class="lexi-table-link" data-table-id="lexi-content-anxiety-extended-release" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-anxiety-extended-release')">table 9</a>)</span><span class="table-link" style="display:none;">Anxiety (Extended Release)</span>, depression (≥2%), emotional lability (2% to 3%), irritability (5% to 8%), lethargy (3% to 8%), loss of consciousness (children: ≥2%), nightmares (3% to 4%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Anxiety (Extended Release)" frame="border" id="lexi-content-anxiety-extended-release" rules="all">
<caption style="text-align:center;">
<b>Guanfacine: Adverse Reaction: Anxiety (Extended Release)</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Guanfacine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Guanfacine)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Children and adolescents</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Flexible dose</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Extended-release tablets</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Attention-deficit/hyperactivity disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">157</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">155</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">Respiratory: Asthma (≥2%)</p>
<p style="text-indent:-2em;margin-left:6em;">Miscellaneous: Fever (8%) (Biederman 2008)</p>
<p style="text-indent:-2em;margin-left:4em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:6em;">Cardiovascular: Atrioventricular block</p>
<p style="text-indent:-2em;margin-left:6em;">Dermatologic: Pallor</p>
<p style="text-indent:-2em;margin-left:6em;">Hepatic: Increased serum alanine aminotransferase</p>
<p style="text-indent:-2em;margin-left:6em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:6em;">Nervous system: Asthenia, seizure</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (all formulations):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, cardiac fibrillation, chest pain, edema, heart block, heart failure, hypertensive encephalopathy (with abrupt discontinuation), palpitations, rebound hypertension (with abrupt discontinuation) (Martinez-Raga 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, dermatitis, exfoliative dermatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Erectile dysfunction, nocturia, urinary frequency</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebrovascular accident, confusion, hallucination, malaise, nervousness, paresthesia, tremor, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, lower extremity pain, lower limb cramp, myalgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea</p></div>
<div class="block coi drugH1Div" id="F178156"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to guanfacine or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F178143"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with severe coronary insufficiency, recent MI, or a history of bradycardia, cardiovascular disease, heart block, hypotension, or syncope. Cautious use is also recommended in patients with conditions that predispose them to syncope (eg, orthostasis, dehydration).</p>
<p style="text-indent:-2em;margin-left:4em;">• Cerebrovascular disease: Use with caution in patients with cerebrovascular disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with chronic hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with chronic renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Product interchangeability: Formulations of guanfacine (immediate release versus extended release) are not interchangeable on a mg to mg basis because bioavailability, C<sub>max</sub>, and T<sub>max</sub> vary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• ADHD treatment: Appropriate use: Recommended to be used as part of a comprehensive treatment program for attention-deficit disorders; safety and efficacy of long-term use for the treatment of ADHD (&gt;2 years) have not been established (Sallee 2009).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878478"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Prior to treatment with medications for attention-deficit/hyperactivity disorder (ADHD), the American Heart Association and the American Academy of Pediatrics recommend that all children and adolescents diagnosed with ADHD have a thorough cardiovascular assessment, including patient and family health histories, evaluation of all medications used (prescribed and over-the-counter), and a physical examination focused on cardiovascular disease risk factors. An ECG is not mandatory but is reasonable to consider prior to stimulant medication therapy. Prompt evaluation and appropriate referral and testing, if warranted, should occur if any cardiac symptoms are present (Vetter 2008).</p></div>
<div class="block foc drugH1Div" id="F178152"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg, 2 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Intuniv: 1 mg, 2 mg, 3 mg, 4 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg, 2 mg, 3 mg, 4 mg</p></div>
<div class="block geq drugH1Div" id="F178139"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F178159"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (guanFACINE HCl ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $10.49</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $10.49</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3 mg (per each): $10.49</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg (per each): $10.49</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Intuniv Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $11.66</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $11.66</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3 mg (per each): $11.66</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg (per each): $11.66</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (guanFACINE HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $0.87 - $1.27</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $1.18 - $2.01</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867091"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Intuniv XR: 1 mg, 2 mg, 3 mg, 4 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg, 2 mg, 3 mg, 4 mg</p></div>
<div class="block adip drugH1Div" id="F53566993"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">Guanfacine is a more selective alpha<sub>2</sub>-agonist than clonidine; therefore, has less sedation and dizziness associated with use than clonidine; withdrawal effects less commonly occur due to its longer half-life.</p>
<p style="text-indent:0em;margin-top:2em;">Medications used to treat attention-deficit/hyperactivity disorder (ADHD) should be part of a total treatment program that may include other components, such as psychological, educational, and social measures. Long-term usefulness of guanfacine for the treatment of ADHD should be periodically re-evaluated in patients receiving the drug for extended periods of time.</p></div>
<div class="block admp drugH1Div" id="F52612957"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral:</p>
<p style="text-indent:-2em;margin-left:2em;">Immediate release: Take at bedtime to minimize somnolence.</p>
<p style="text-indent:-2em;margin-left:2em;">Extended release: Take at the same time each day (either morning or evening); swallow tablet whole with water, milk, or other liquid; do not crush, break, or chew; do not administer with high-fat meal.</p></div>
<div class="block adm drugH1Div" id="F9612516"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: IR tablets are usually given at bedtime to minimize somnolence. Formulations (immediate release versus extended release) are not interchangeable.</p>
<p style="text-indent:-2em;margin-left:2em;">Bariatric surgery: Tablet, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Do not cut, crush, or chew. Switch to IR formulation. Dose adjustment may be necessary since bioavailability of the IR formulation differs from extended release.</p></div>
<div class="block sts drugH1Div" id="F9612502"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Immediate release: Store at 20°C to 25°C (68°F to 77°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Extended release: Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F).</p></div>
<div class="block usep drugH1Div" id="F53567169"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Immediate release: Management of hypertension alone or in combination with other hypertensive agents, especially thiazide-type diuretics (FDA approved ages ≥12 years and adults); has also been used for the treatment of attention-deficit/hyperactivity disorder (ADHD), tic disorder or Tourette syndrome with or without ADHD, and autism spectrum disorder with ADHD comorbidity.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Although FDA approved for hypertension, pediatric consensus guidelines do not include guanfacine as a therapeutic option; use has been replaced by other agents (AAP [Flynn 2017]).</p>
<p style="text-indent:-2em;margin-left:2em;">Extended release: Treatment of ADHD as monotherapy or adjunctive therapy with stimulant medication (FDA approved in ages 6 to 17 years).</p></div>
<div class="block mst drugH1Div" id="F178195"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">GuanFACINE may be confused with guaiFENesin, guanabenz, guanidine</p>
<p style="text-indent:-2em;margin-left:4em;">Intuniv may be confused with Invega</p>
<p style="text-indent:-2em;margin-left:4em;">Tenex may be confused with Entex, Xanax</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Guanfacine is identified in the Beers Criteria as a potentially inappropriate medication to be avoided for the treatment of hypertension in patients 65 years and older due to high risk of CNS adverse effects and risk of bradycardia and orthostatic hypotension associated with central alpha agonists (Beers Criteria [AGS 2023]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Tenex [US] may be confused with Kinex brand name for biperiden [Mexico]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F9837647"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major), OCT1, OCT2; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F178147"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the CNS depressant effect of GuanFACINE.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers: Alpha2-Agonists may enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the Alpha2-Agonist is abruptly withdrawn.  Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of GuanFACINE. Management: Increase extended-release guanfacine dose by up to double when initiating guanfacine in patients taking CYP3A4 inducers or if initiating a CYP3A4 inducer in a patient already taking extended-release guanfacine. Monitor for reduced guanfacine efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of GuanFACINE. Management: Increase extended-release guanfacine dose by up to double when initiating guanfacine in patients taking CYP3A4 inducers or if initiating a CYP3A4 inducer in a patient already taking extended-release guanfacine. Monitor for reduced guanfacine efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of GuanFACINE. Management: Reduce the extended-release guanfacine dose 50% when combined with a moderate CYP3A4 inhibitor. Monitor for increased guanfacine toxicities when these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of GuanFACINE. Management: Reduce the extended-release guanfacine dose 50% when combined with a strong CYP3A4 inhibitor. Monitor for increased guanfacine toxicities when these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Bradycardia-Causing Agents may enhance the arrhythmogenic effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Fingolimod.  Management: Consult with the prescriber of any bradycardia-causing agent to see if the agent could be switched to an agent that does not cause bradycardia prior to initiating fingolimod. If combined, perform continuous ECG monitoring after the first fingolimod dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirtazapine: May diminish the antihypertensive effect of Alpha2-Agonists. Management: Consider avoiding concurrent use.  If the combination cannot be avoided, monitor for decreased effects of alpha2-agonists if mirtazapine is initiated/dose increased, or increased effects if mirtazapine is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products.  Management: Consider alternatives to this combination when possible. If combined, dose reduction or discontinuation of one or more CNS depressants (including the oxybate salt product) should be considered. Interrupt oxybate salt treatment during short-term opioid use<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ponesimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Ponesimod.  Management: Avoid coadministration of ponesimod with drugs that may cause bradycardia when possible. If combined, monitor heart rate closely and consider obtaining a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less than 55 bpm.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazosin: Antihypertensive Agents may enhance the hypotensive effect of Prazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin/Norepinephrine Reuptake Inhibitors: May diminish the therapeutic effect of Alpha2-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod.  Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. If combined, consider obtaining a cardiology consult regarding patient monitoring.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terazosin: Antihypertensive Agents may enhance the hypotensive effect of Terazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May diminish the antihypertensive effect of Alpha2-Agonists. Management: Consider avoiding this combination. If used, monitor for decreased effects of the alpha2-agonist. Exercise great caution if discontinuing an alpha2-agonist in a patient receiving a TCA.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urapidil: Antihypertensive Agents may enhance the hypotensive effect of Urapidil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: GuanFACINE may increase the serum concentration of Valproate Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F45501431"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Grapefruit juice/products: Guanfacine serum concentrations may be increased when taken with grapefruit juice/products. Management: Consider reducing guanfacine dose by 50% when taking grapefruit juice/products concomitantly; monitor for increased effects/toxicity.</p></div>
<div class="block dic drugH1Div" id="F9612515"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Extended-release tablets: Do not administer with a high-fat meal due to increased exposure.</p></div>
<div class="block rep_considerations drugH1Div" id="F58086874"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Medications considered acceptable for the treatment of chronic hypertension during pregnancy may generally be continued in patients trying to conceive. Guanfacine is not considered a preferred agent for use in pregnant patients; consider transitioning to a preferred agent in patients planning to become pregnant (ACC/AHA [Whelton 2018]; ACOG 2019; NICE 2019).</p></div>
<div class="block pri drugH1Div" id="F9612487"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Outcome data related to guanfacine use during pregnancy are limited (Karesoja 1981; Philipp 1980). In one study of 30 women treated with guanfacine for hypertension during pregnancy, the majority (n=25) experience sedation; dry mouth and dizziness were also reported (Philipp 1980).</p>
<p style="text-indent:0em;margin-top:2em;">Chronic maternal hypertension is associated with adverse events in the fetus/infant. Chronic maternal hypertension may increase the risk of birth defects, low birth weight, premature delivery, stillbirth, and neonatal death. Actual fetal/neonatal risks may be related to the duration and severity of maternal hypertension. Untreated chronic hypertension may also increase the risks of adverse maternal outcomes, including gestational diabetes, preeclampsia, delivery complications, stroke, and myocardial infarction (ACOG 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Patients with preexisting hypertension may continue their medication during pregnancy unless contraindications exist (ESC [Regitz-Zagrosek 2018]). When treatment of chronic hypertension is initiated during pregnancy, agents other than guanfacine may be preferred (ACOG 2019; ESC [Cífková 2020]; ESC [Regitz-Zagrosek 2018]; SOGC [Magee 2022]).</p>
<p style="text-indent:0em;margin-top:2em;">Because there are limited data related to the use of guanfacine in pregnancy (Cohen 2023; Ornoy 2021), discontinue guanfacine for the treatment of attention deficit/hyperactivity disorder (ADHD) during pregnancy (Ornoy 2021). Data collection to monitor pregnancy and infant outcomes following exposure to ADHD medications is ongoing. Health care providers are encouraged to enroll patients exposed to Intuniv during pregnancy in the National Pregnancy Registry for ADHD Medications (866-961-2388).</p></div>
<div class="block mopp drugH1Div" id="F53567133"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Heart rate, blood pressure, consider ECG monitoring in patients with history of heart disease or concurrent use of medications affecting cardiac conduction.</p>
<p style="text-indent:-2em;margin-left:2em;">Attention-deficit/hyperactivity disorder (ADHD): Evaluate patients for cardiac disease prior to initiation of therapy for ADHD with thorough medical history, family history, and physical exam; consider ECG; perform ECG and echocardiogram if findings suggest cardiac disease; promptly conduct cardiac evaluation in patients who develop chest pain, unexplained syncope, or any other symptom of cardiac disease during treatment.</p></div>
<div class="block pha drugH1Div" id="F178142"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Guanfacine is a selective alpha<sub>2A</sub>-adrenoreceptor agonist that reduces sympathetic nerve impulses, resulting in reduced sympathetic outflow and a subsequent decrease in vasomotor tone and heart rate.  In addition, guanfacine preferentially binds postsynaptic alpha<sub>2A</sub>-adrenoreceptors in the prefrontal cortex and has been theorized to improve delay-related firing of prefrontal cortex neurons. As a result, underlying working memory and behavioral inhibition are affected; thereby improving symptoms associated with ADHD.  Guanfacine is not a CNS stimulant. </p></div>
<div class="block phk drugH1Div" id="F178155"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>When dosed at same mg dose, the extended-release product has a lower peak serum concentration (60% lower) and AUC (43% lower) compared with the immediate-release formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Readily absorbed.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Antihypertensive effect: 24 hours following single dose</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: 6.3 L/kg</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release: V<sub>d</sub> (apparent): Children ≥6 years: 23.7 L/kg; Adolescent: 19.9 L/kg (Boellner 2007)</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~70%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP3A4. Approximately 50% of clearance is hepatic.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability:</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: ~80%</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release (relative to immediate release): 58%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: ~17 hours (range: 10 to 30 hours)</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release: Children ≥6 years: 14.4 hours; Adolescents: 18 hours (Boellner 2007); Adults: 18 ± 4 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum:</p>
<p style="text-indent:-2em;margin-left:4em;">Immediate release: 2.6 hours (range: 1 to 4 hours)</p>
<p style="text-indent:-2em;margin-left:4em;">Extended release: Children ≥6 years and Adolescents: 5 hours (Boellner 2007); Adults: 4 to 8 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~50% [40% to 75% of dose] as unchanged drug)</p></div>
<div class="block phksp drugH1Div" id="F51196158"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: In patients with renal impairment, clearance is reduced; plasma levels are only slightly increased. In patients on hemodialysis, dialysis clearance was ~15% of total clearance.</p>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: Exposure to guanfacine was slightly higher in children (6 to 12 years of age) compared with adolescents (13 to 17 years of age); data suggest this difference corresponds with patient weight rather than age; clinical significance is not defined (Tsuda 2019).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F178160"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Intuniv</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Intuniv</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Estulic | Intuniv</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Intuniv</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Intuniv</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Intuniv</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Intuniv</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Intuniv</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Intuniv</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Intuniv</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Intuniv</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Estulic</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Estulic</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Intuniv</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Intuniv</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Estulic | Intuniv</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Estulic | Intuniv</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Estulic</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Estulic</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Intuniv</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Intuniv</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Estulic</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Estulic | Intuniv</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Guanfacine | Guanfacine extended release | Guanfacine HCL | Tenex</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Estulic</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Entulic | Intuniv</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Estulic</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Estulic</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Estulic</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Estulic</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics/American Heart Association Clarification of Statement on Cardiovascular Evaluation and Monitoring of Children and Adolescents With Heart Disease Receiving Medications for ADHD; available at: http://americanheart.mediaroom.com/index.php?s=43&amp;item=422.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30575676">
<a name="30575676"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 203: Chronic hypertension in pregnancy. <i>Obstet Gynecol</i>. 2019;133(1):e26-e50. doi: 10.1097/AOG.0000000000003020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/30575676/pubmed" id="30575676" target="_blank">30575676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21518977">
<a name="21518977"></a>Aronow WS, Fleg JL, Pepine CJ, et al; ACCF Task Force. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. <i>Circulation</i>. 2011;123(21):2434-2506. doi: 10.1161/CIR.0b013e31821daaf6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/21518977/pubmed" id="21518977" target="_blank">21518977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12894610">
<a name="12894610"></a>Bassarath L. Medication Strategies in Childhood Aggression: A Review. <i>Can J Psychiatry.</i> 2003;48(6):367-373.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/12894610/pubmed" id="12894610" target="_blank">12894610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18166547">
<a name="18166547"></a>Biederman J, Melmed RD, Patel A, et al. A Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine Extended Release in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder. <i>Pediatrics.</i> 2008;121(1):e73-e84.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/18166547/pubmed" id="18166547" target="_blank">18166547</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19179940">
<a name="19179940"></a>Biederman J, Melmed RD, Patel A, et al. Long-Term, Open-Label Extension Study of Guanfacine Extended Release in Children and Adolescents With ADHD. <i>CNS Spectr.</i> 2008;13(12):1047-1055.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/19179940/pubmed" id="19179940" target="_blank">19179940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17723079">
<a name="17723079"></a>Boellner SW, Pennick M, Fiske K, et al. Pharmacokinetics of a Guanfacine Extended-Release Formulation in Children and Adolescents With Attention-Deficit-Hyperactivity Disorder. <i>Pharmacotherapy. </i>2007;27(9):1253-1262.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/17723079/pubmed" id="17723079" target="_blank">17723079</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7559307">
<a name="7559307"></a>Chappell PB, Riddle MA, Scahill L, et al. Guanfacine Treatment of Comorbid Attention-Deficit Hyperactivity Disorder and Tourette's Syndrome: Preliminary Clinical Experience. <i>J Am Acad Child Adolesc Psychiatry.</i> 1995;34(9):1140-1146.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/7559307/pubmed" id="7559307" target="_blank">7559307</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12748199">
<a name="12748199"></a>Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. <i>JAMA.</i> 2003;289(19):2560-2571.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/12748199/pubmed" id="12748199" target="_blank">12748199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31841131">
<a name="31841131"></a>Cífková R, Johnson MR, Kahan T, et al. Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension.<i> Eur Heart J Cardiovasc Pharmacother</i>. 2020;6(6):384-393. doi:10.1093/ehjcvp/pvz082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/31841131/pubmed" id="31841131" target="_blank">31841131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36445458">
<a name="36445458"></a>Cohen JM, Srinivas C, Furu K, Cesta CE, Reutfors J, Karlstad Ø. Prevalence trends and individual patterns of ADHD medication use in pregnancy in Norway and Sweden, 2010-2019. <i>Eur J Clin Pharmacol</i>. 2023;79(1):173-180. doi:10.1007/s00228-022-03428-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/36445458/pubmed" id="36445458" target="_blank">36445458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32905677">
<a name="32905677"></a>Cortese S. Pharmacologic treatment of attention deficit-hyperactivity disorder. <i>N Engl J Med</i>. 2020;383(11):1050-1056. doi:10.1056/NEJMra1917069<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/32905677/pubmed" id="32905677" target="_blank">32905677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12469007">
<a name="12469007"></a>Cummings DD, Singer HS, Krieger M, Miller TL, Mahone EM. Neuropsychiatric effects of guanfacine in children with mild tourette syndrome: a pilot study. <i>Clin Neuropharmacol</i>. 2002;25(6):325-332.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/12469007/pubmed" id="12469007" target="_blank">12469007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19476419">
<a name="19476419"></a>Dopheide JA, Pliszka SR. Attention-deficit-hyperactivity disorder: an update. <i>Pharmacotherapy.</i> 2009;29(6):656-679.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/19476419/pubmed" id="19476419" target="_blank">19476419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28827377">
<a name="28827377"></a>Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. <i>Pediatrics</i>. 2017;140(3):e20171904.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/28827377/pubmed" id="28827377" target="_blank">28827377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26934393">
<a name="26934393"></a>Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/26934393/pubmed" id="26934393" target="_blank">26934393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24243703">
<a name="24243703"></a>Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention [published online November 15, 2013]. <i>Hypertension</i>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/24243703/pubmed" id="24243703" target="_blank">24243703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Guanfacine.1">
<a name="Guanfacine.1"></a>Guanfacine Hydrochloride [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals LLC; August 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18552703">
<a name="18552703"></a>Handen BL, Sahl R, Hardan AY. Guanfacine in Children With Autism and/or Intellectual Disabilities. <i>J Dev Behav Pediatr.</i> 2008;29(4):303-308.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/18552703/pubmed" id="18552703" target="_blank">18552703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24472251">
<a name="24472251"></a>Hirota T, Schwartz S, Correll CU. Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy. <i>J Am Acad Child Adolesc Psychiatry</i>. 2014;53(2):153-173. doi:10.1016/j.jaac.2013.11.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/24472251/pubmed" id="24472251" target="_blank">24472251</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30064718">
<a name="30064718"></a>Huss M, McBurnett K, Cutler AJ, Hervás A, Bliss C, Gao J, Dirks B, Newcorn JH. Distinguishing the efficacy and sedative effects of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. <i>Eur Neuropsychopharmacol</i>. 2019;29(3):432-443.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/30064718/pubmed" id="30064718" target="_blank">30064718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Intuniv.1">
<a name="Intuniv.1"></a>Intuniv (guanfacine) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America, Inc; August 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9231887">
<a name="9231887"></a>Kaplan NM, Sever PS. Combination therapy: a key to comprehensive patient care. <i>Am J Hypertens.</i> 1997;10(7, pt 2):127S.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/9231887/pubmed" id="9231887" target="_blank">9231887</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Karesoja.1">
<a name="Karesoja.1"></a>Karesoja M, Takkunen H. Guanfacine, a new centrally acting antihypertensive agent in long-term therapy. <i>Curr Ther Res</i> 1981;29:60-65.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6994783">
<a name="6994783"></a>Kugler J, Seus R, Krauskopf R, Brecht HM, Raschig A. Differences in psychic performance with guanfacine and clonidine in normotensive subjects. <i>Br J Clin Pharmacol</i>. 1980;10 suppl 1(suppl 1):71S-80S. doi:10.1111/j.1365-2125.1980.tb04909.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/6994783/pubmed" id="6994783" target="_blank">6994783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35577426">
<a name="35577426"></a>Magee LA, Smith GN, Bloch C, et al. Guideline no. 426: hypertensive disorders of pregnancy: diagnosis, prediction, prevention, and management. <i>J Obstet Gynaecol Can</i>. 2022;44(5):547-571.e1. doi:10.1016/j.jogc.2022.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/35577426/pubmed" id="35577426" target="_blank">35577426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23160939">
<a name="23160939"></a>Martinez-Raga J, Knecht C, Szerman N, Martinez MI. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder. <i>CNS Drugs</i>. 2013;27(1):15-30. doi:10.1007/s40263-012-0019-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/23160939/pubmed" id="23160939" target="_blank">23160939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19833104">
<a name="19833104"></a>Mitchell HA, Weinshenker D. Good night and good luck: norepinephrine in sleep pharmacology. <i>Biochem Pharmacol</i>. 2010;79(6):801-809. doi:10.1016/j.bcp.2009.10.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/19833104/pubmed" id="19833104" target="_blank">19833104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9655566">
<a name="9655566"></a>Moser M, Black HR. The role of combination therapy in the treatment of hypertension. <i>Am J Hypertens.</i> 1998;11(6, pt 2):73S-78S, 95S-100S.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/9655566/pubmed" id="9655566" target="_blank">9655566</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28723227">
<a name="28723227"></a>Murphy TK, Fernandez TV, Coffey BJ, et al. Extended-release guanfacine does not show a large effect on tic severity in children with chronic tic disorders. <i>J Child Adolesc Psychopharmacol</i>. 2017;27(9):762-770.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/28723227/pubmed" id="28723227" target="_blank">28723227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24290467">
<a name="24290467"></a>Murphy TK, Lewin AB, Storch EA, Stock S; American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice parameter for the assessment and treatment of children and adolescents with tic disorders. <i>J Am Acad Child Adolesc Psychiatry</i>. 2013;52(12):1341-1359.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/24290467/pubmed" id="24290467" target="_blank">24290467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Attention deficit hyperactivity disorder: diagnosis and management. NICE clinical guideline NG87. London, UK: National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ng87/chapter/recommendations. Published March 2018. Accessed October 15, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2019">
<a name="NICE.2019"></a>National Institute for Health and Care Excellence (NICE). Hypertension in pregnancy: diagnosis and management. https://www.nice.org.uk/guidance/ng133. Published June 25, 2019. Accessed December 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33245274">
<a name="33245274"></a>Ornoy A, Koren G. The effects of drugs used for the treatment of attention deficit hyperactivity disorder (ADHD) on pregnancy outcome and breast-feeding: a critical review. <i>Curr Neuropharmacol.</i> 2021;19(11):1794-1804. doi:10.2174/1570159X18666201127164000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/33245274/pubmed" id="33245274" target="_blank">33245274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18676566">
<a name="18676566"></a>Perrin JM, Friedman RA, Knilans TK; Black Box Working Group; Section on Cardiology and Cardiac Surgery. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. <i>Pediatrics</i>. 2008;122(2):451-453.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/18676566/pubmed" id="18676566" target="_blank">18676566</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6994768">
<a name="6994768"></a>Philipp E. Guanfacine in the treatment of hypertension due to pre-eclamptic toxaemia in thirty women. <i>Br J Clin Pharmacol.</i> 1980;10(suppl 1):137-140.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/6994768/pubmed" id="6994768" target="_blank">6994768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17581453">
<a name="17581453"></a>Pliszka S and AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. <i>Am Acad Child Adolesc Psychiatry.</i> 2007;46(7):894-921.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/17581453/pubmed" id="17581453" target="_blank">17581453</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15319020">
<a name="15319020"></a>Posey DJ, Puntney JI, Sasher TM, et al. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. <i>J Child Adolesc Psychopharmacol.</i> 2004;14(2):233-241.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/15319020/pubmed" id="15319020" target="_blank">15319020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22397999">
<a name="22397999"></a>Pringsheim T, Doja A, Gorman D, et al. Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy. <i>Can J Psychiatry</i>. 2012;57(3):133-143.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/22397999/pubmed" id="22397999" target="_blank">22397999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31061208">
<a name="31061208"></a>Pringsheim T, Okun MS, Müller-Vahl K, et al; Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology (AAN). Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. <i>Neurology</i>. 2019;92(19):896-906.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/31061208/pubmed" id="31061208" target="_blank">31061208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6150002">
<a name="6150002"></a>Reid JL, Campbell BC, Hamilton CA. Withdrawal reactions following cessation of central alpha-adrenergic receptor agonists. <i>Hypertension</i>. 1984;6(5 pt 2):II71-II75. doi:10.1161/01.hyp.6.5_pt_2.ii71<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/6150002/pubmed" id="6150002" target="_blank">6150002</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19519256">
<a name="19519256"></a>Sallee FR, Lyne A, Wigal T, et al. Long-Term Safety and Efficacy of Guanfacine Extended Release in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder. <i>J Child Adolesc Psychopharmacol.</i> 2009;19(3):215-226.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/19519256/pubmed" id="19519256" target="_blank">19519256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19106767">
<a name="19106767"></a>Sallee FR, McGough J, Wigal T, et al. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. <i>J Am Acad Child Adolesc Psychiatry.</i> 2009;48(2):155-165.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/19106767/pubmed" id="19106767" target="_blank">19106767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17069547">
<a name="17069547"></a>Scahill L, Aman MG, McDougle CJ, et al. A prospective open trial of guanfacine in children with pervasive developmental disorders. <i>J Child Adolesc Psychopharmacol.</i> 2006;16(5):589-598.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/17069547/pubmed" id="17069547" target="_blank">17069547</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11431228">
<a name="11431228"></a>Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. <i>Am J Psychiatry</i>. 2001;158(7):1067-1074.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/11431228/pubmed" id="11431228" target="_blank">11431228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Shanahan.1">
<a name="Shanahan.1"></a>Shanahan JF, Lebowitz H, eds. <i>Goodman &amp; Gilman's: The Pharmacological Basis of Therapeutics</i>. 13th ed. McGraw-Hill Education; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32394557">
<a name="32394557"></a>Solmi M, Fornaro M, Ostinelli EG, et al. Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. <i>World Psychiatry</i>. 2020;19(2):214-232. doi:10.1002/wps.20765<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/32394557/pubmed" id="32394557" target="_blank">32394557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19877974">
<a name="19877974"></a>Spencer TJ, Greenbaum M, Ginsberg LD, et al. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. <i>J Child Adolesc Psychopharmacol.</i> 2009;19(5):501-510.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/19877974/pubmed" id="19877974" target="_blank">19877974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23757186">
<a name="23757186"></a>Spiller HA, Hays HL, Aleguas A Jr. Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management. <i>CNS Drugs</i>. 2013;27(7):531-543. doi:10.1007/s40263-013-0084-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/23757186/pubmed" id="23757186" target="_blank">23757186</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31563330">
<a name="31563330"></a>Tsuda Y, Matsuo Y, Matsumoto S, Wajima T. Population pharmacokinetic and exposure-response analyses of guanfacine in Japanese pediatric ADHD patients. <i>Drug Metab Pharmacokinet</i>. 2019;34(6):365-371. doi:10.1016/j.dmpk.2019.07.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/31563330/pubmed" id="31563330" target="_blank">31563330</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34607580">
<a name="34607580"></a>van Stralen J, Gill SK, Reaume CJ, Handelman K. A retrospective medical chart review of clinical outcomes in children and adolescents with attention-deficit/hyperactivity disorder treated with guanfacine extended-release in routine Canadian clinical practice. <i>Child Adolesc Psychiatry Ment Health</i>. 2021;15(1):55. doi:10.1186/s13034-021-00402-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/34607580/pubmed" id="34607580" target="_blank">34607580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18427125">
<a name="18427125"></a>Vetter VL, Elia J, Erickson CH, et al; American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee; American Heart Association Council on Cardiovascular Nursing. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. <i>Circulation</i>. 2008;117(18):2407-2423.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/18427125/pubmed" id="18427125" target="_blank">18427125</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23099282">
<a name="23099282"></a>Weisman H, Qureshi IA, Leckman JF, Scahill L, Bloch MH. Systematic review: pharmacological treatment of tic disorders--efficacy of antipsychotic and alpha-2 adrenergic agonist agents. <i>Neurosci Biobehav Rev</i>. 2013;37(6):1162-1171.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/23099282/pubmed" id="23099282" target="_blank">23099282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29133356">
<a name="29133356"></a>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published online November 13, 2017]. <i>Hypertension</i>. doi:10.1161/HYP.0000000000000065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/29133356/pubmed" id="29133356" target="_blank">29133356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22176941">
<a name="22176941"></a>Wilens TE, Bukstein O, Brams M, et al. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. <i>J Am Acad Child Adolesc Psychiatry. </i>2012;51(1):74-85.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/22176941/pubmed" id="22176941" target="_blank">22176941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31570648">
<a name="31570648"></a>Wolraich ML, Hagan JF Jr, Allan C, Chan E, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. <i>Pediatrics</i>. 2019;144(4):e20192528.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/guanfacine-pediatric-drug-information/abstract-text/31570648/pubmed" id="31570648" target="_blank">31570648</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 15555 Version 502.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
